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Manypatientswithbreathlessnessandchronicobstructivelungdiseasearediagnosedwitheitherasthma,COPD,or—frequently—
mixed disease. More commonly, patients with uncharacterized breathlessness are treated with therapies that target asthma and
COPD rather than one of these diseases. This common practice represents the diﬃculty in distinguishing these disorders clinically,
particularly in patients with a history that does not easily diﬀerentiate asthma from COPD. A common clinical scenario is an
older former smoker with partially reversible or ﬁxed airﬂow obstruction and evidence of atopy, demonstrating “overlap” features
of asthma and COPD. We stress that asthma-COPD overlap syndrome becomes more prevalent with advancing age as patients
respondlessfavorablytoguideline-recommendeddrugtherapy.Wereviewthesimilaritiesanddiﬀerencesinclinicalcharacteristics
between these disorders, and their physiologic and inﬂammatory proﬁles within the context of the aging patient. We underscore
the diﬃculties in diﬀerentiating asthma from COPD in current or former smokers, share our institutional experience with overlap
syndrome, and highlight the need for new research to better characterize and investigate this important clinical phenotype.
1.Introduction
The general internist, allergist, and pulmonologist common-
lyencounteradultpatientswithclinicalfeaturesofbothasth-
maandchronicobstructivepulmonarydisease(COPD).Dif-
ferentiatingtheunderlyingcauseoftheirsymptomsbecomes
diﬃcult and often leads to blanket therapy directed towards
airway hyperreactivity (AHR), airway inﬂammation, airﬂow
obstruction, and allergic disease. A salient example is an old-
er patient with a history of seasonal allergies and asthma, a
current or past smoking history, and progressive symptoms
of acute-on-chronic dyspnea. They may demonstrate ﬁxed
airﬂow obstruction or partial reversibility on spirometric
testing, an elevated total IgE, and a slightly increased nitric
oxide level. Does such a patient have COPD with AHR, re-
modeled asthma that has progressed to partially reversible
or “ﬁxed” airﬂow obstruction, or overlapping COPD and
asthma—the so-called asthma-COPD overlap syndrome?I s
some degree of airﬂow obstruction simply related to natural
aging of the lung (a decline in FEV1 exceeding the predicted
25to30mLperyear),andshouldthisbetreated?Theseques-
tions beget further questions regarding the need to distin-
guish the components of asthma-COPD overlap and the as-
sociated treatment implications, including drug side eﬀects,
compliance, and variable response to drug therapy with ad-
vancing age. This becomes even more relevant in the elderly
population where the overlap syndrome is prevalent.
In this paper we review the data which address the bio-
logic,clinical,anddiagnosticdiﬀerencesbetweenasthmaand
COPD. We will also highlight several areas of overlap be-
tween these disorders supporting the need to clinically deﬁne
this subgroup of patients with obstructive lung disease.2 Journal of Allergy
Further, we aim to deﬁne the overlap syndrome based on the
currentunderstanding intheliteratureandourclinicalexpe-
rience and practice, while underscoring the challenges that
remain in understanding this important entity. Ultimately,
we propose a work-up and treatment algorithm which ﬁts
our patient population, and we raise important questions for
future studies needed to advance the recognition and man-
agement of asthma-COPD overlap.
2. Asthma versusCOPD
2.1. Accepted Diﬀerences. In theory, asthma and COPD are
diﬀerent diseases each with a unique natural history and pa-
thophysiology. The British Hypothesis holds that asthma and
COPD are distinct diseases that develop by unique mecha-
nisms [1]. It is widely accepted that asthma generally mani-
festsasintermittent andreversible airwayobstruction,where-
as COPD is progressive and irreversible [2–4]. Based on cur-
rent guidelines, the postbronchodilator response in asthma
shows complete reversibility of airway obstruction. In COPD,
there is either no reversibility (i.e., ﬁxed obstruction) or there
is partial reversibility of airway obstruction following bron-
chodilator, described as “COPD with partial reversibility”
[5]. In this latter entity, one can demonstrate reversibility as
an improvement in lung function, but the patient remains
obstructed on spirometric measurements (hence, the desig-
nation of “COPD” rather than “asthma”). Preserved carbon
monoxidediﬀusioncapacity(DLCO)onPFTandahigherra-
tio of airway-to-lung parenchymal abnormalities (on lung
imaging by high-resolution chest tomography) may also dis-
tinguish asthma from COPD [6].
Clinically, the distinction between asthma and COPD is
most apparent at the extremes of age [7], where younger
patients tend to have more asthma symptoms and older pa-
tients (age > 60) tend to have COPD symptoms. A history of
cigarette smoking and evidence of emphysema in an older
patient with spirometric airﬂow obstruction would favor
COPD. A nonsmoking younger patient with a history of
childhood asthma or wheezing and atopy with reversible air-
ﬂowobstructionwouldfavorasthma.Thoughsymptomscan
oftenoverlap,Beehandcolleaguesdevelopedaquestionnaire
to diﬀerentiate asthma and COPD [8]. On a scale of 1 to 15,
thequestionnaireperformedbestatacutoﬀof7withasensi-
tivity of 87.6% for COPD, though ∼20% of patients had
overlap features (scores 6–8). Practically speaking for the
clinician,thedistinctionbetweenasthmaandCOPDislarge-
ly based on clinical ﬁndings.
Major diﬀerences exist in the structural and inﬂammato-
ry signatures of asthma and COPD when studied in isolated,
well-deﬁned populations [9–12]. These include elevated IgE,
induction of Th2 cells, eosinophilic inﬁltration, reticular
basement membrane thickening, and smooth muscle hyper-
plasia in asthma. In contrast, increased neutrophils, induc-
tion of Th1a n dT h17 cells, TGFβ-induced small airway
ﬁbrosis, goblet cell hyperplasia, and MMP elastic tissue
destruction are typically found in COPD [13, 14]. Bron-
choscopic endobronchial biopsies have shown smooth mus-
cle cell hypertrophy and chronic inﬂammation in asthma
[10,15,16].Endobronchialbiopsyhasalsodistinguishedtwo
inﬂammatory subtypes of severe asthma [17]. Though there
are major histologic diﬀerences between asthma and COPD,
endobronchial biopsy is not widely used in the workup and
management of obstructive lung disease [18] as the risk-
beneﬁt proﬁle is often unfavorable. Animal and human stud-
ies suggest that cytokine proﬁles may be used to help distin-
guish between asthma and COPD. However, these data also
indicatethatadiseasecontinuumexistsinsomepatientswith
elements of both diseases [1]. Ongoing research using ex-
halednitricoxide andotherexhaledbiomarkersmayprovide
reliable biological parameters to aid in diagnosis [19–22].
Existing treatment options for asthma and COPD high-
light some important diﬀerences [23, 24]. For example,
COPD with reduced DLCO may qualify for supplemental
oxygen therapy [25] and referral to a pulmonary rehabilita-
tion program [26, 27]. Severe allergic asthma with an appro-
priate high level of serum IgE may qualify for treatment with
omalizumab [28, 29], and, in those with allergic asthma not
well controlled on ICS, leukotriene receptor antagonists [30]
or 5-lipoxygenase inhibitors may improve symptoms. Bron-
chial thermoplasty, a novel therapy that uses endobronchial
radiofrequency ablation to reduce airway smooth muscle
mass, reduces asthma symptoms and rates of exacerbation
[31]. However, the link between clinical classiﬁcation or di-
agnosis, pathophysiology, and guideline-based treatments
can be opaque in practice due to the lack of simple tests that
can reliably distinguish the two diseases. Clinicians will con-
sequently lump together asthma and COPD treating them as
one condition.
2.2. Diﬃcult Separation, Supporting an Overlap Syndrome.
ManycliniciansrecognizethatasthmaandCOPDcanappear
more similar than dissimilar clinically. Typical symptoms of
dyspnea, wheezing, or cough do not have the sensitivity or
speciﬁcity to distinguish these two disorders among older
adultsafterexcludingcomorbidconditionssuchasheartfail-
ure, diastolic dysfunction, aspiration, GERD, or vocal cord
dysfunction. According to Soriano et al., asthma and COPD
are diﬃcult to diﬀerentiate because (1) the conditions are
viewed as part of a disease continuum; (2) they have strong
overlapping features; (3) there is no incentive to diﬀerentiate
whethertheirtreatmentandprognosisarethesame;(4)there
is a lack of clear guidelines as to how the distinction can be
made in clinical practice; (5) uncertain criteria are used by
physicians to classify patients as having asthma or COPD
[7]. Despite years of research and the proliﬁc expansion of
guidelinesfrombothEuropeanandAmericanrespiratoryso-
cieties, distinguishing these two common diseases remains a
daunting challenge.
Recent reviews underscore the pitfalls in diagnosis, man-
agement, and treatment of overlap syndrome, asthma, and
COPD[32–35].TheDutchHypothesismaintainsthatasthma
and AHR predispose patients to develop COPD later in life
[36]andthatasthmaandCOPDarediﬀerentexpressionsofa
singledisease(basedonthetimingofenvironmentalandepi-
genetic inﬂuences amidst a common genetic background).
Some authorities argue that obstructive lung disease is aJournal of Allergy 3
progressive disease that begins in early childhood, where
COPD is the ﬁnal manifestation. Recent epidemiologic ﬁnd-
ings, from a long-term cohort study in the United States,
point to asthma as a signiﬁcant risk factor for the future de-
velopment of COPD [37]. Unless there are clear exposures,
such as a prolonged smoking history in a person with severe
emphysema, clinicians recognize that considerable pheno-
typic heterogeneity makes clear distinctions between ob-
structivelungdiseasesproblematic[38,39].Thesechallenges
a r en i c e l yd e m o n s t r a t e db yas e r i e so fp r o - c o nd e b a t e s
between Kraft and Barnes [40, 41].
Not all comparisons between asthma and COPD pathol-
ogy show unique structural diﬀerences. In 100 select patients
with clinically determined asthma and COPD who under-
went endobronchial biopsies, there were no statistically sig-
niﬁcant diﬀerences in key pathologic features [18]. Though
eosinophilicinﬁltrationandbasementmembranethickening
were associated with asthma, the overall diﬀerences in these
features, metaplasia, and epithelial inﬂammation did not
allow for pathologic diﬀerentiation. Airway remodeling and
the lung’s speciﬁc repair responses may account for some of
the pathological similarities reported in asthma and COPD
[42, 43]. These structural similarities in small airways may
contribute to the observed clinical overlap. Up to 50% of
COPD patients can have AHR due to the narrowing of their
distalairwaysandpredispositiontobronchospasm[3].How-
ever, Fabbri et al. showed that despite a similar degree of ﬁx-
ed airway obstruction, asthmatic and COPD airway inﬂam-
mation and structural changes do not appear the same [12].
But as imaging and airﬂow resistance assessment techniques
improve, the small airway changes associated with asthma
and COPD which appear dissimilar may result in a pheno-
typically similar outcome [44]. Limitations inherent to the
diﬀerentpatient cohortsstudied and researchmethodologies
used may confound and limit ﬁnal conclusions regarding a
clear histopathologic-physiologic link.
Asthma and COPD can overlap in their inﬂammatory
sputum proﬁles and lung function. Severe bronchial asthma
with ﬁxed obstruction has an increased number of neutro-
phils similar to COPD [45]. Eosinophilic inﬂammation in
COPD may play a substantial role and be associated with
greater postbronchodilator reversibility [46]. Chronic bron-
chitis or emphysema patients with airway eosinophilia dem-
onstrate increased airway reversibility and respond more
readily to corticosteroid therapy [47–49]. In smokers with
severe obstructive bronchitis, sputum eosinophilia predicts
a beneﬁcial response to prednisone treatment [50]. Evidence
of bronchodilator response (i.e., reversibility) or AHR may
be an important measure not only for diagnosis but also for
prognosis with respect to the rate of lung function decline
and asthma mortality [51, 52]. However, not all studies agree
that bronchodilator responses correlate with the subsequent
rate of lung function decline [53]. Some authors found that
the prognosis in terms of all-cause mortality is strongly cor-
related with age, smoking, and the best attainable FEV1
regardless of reversibility [54]. Given that overlap features
become prevalent with increasing age and a smoking history,
thereare important implications forprognosis regarding this
syndrome.
According to Diaz-Guzman et al., the treatment of asth-
ma and COPD in older adults does not diﬀer from available
guidelinesbutmaybecomplicatedbythepresenceofcomor-
bidities [32]. However, this position fails to grasp the high-
ly variable response to anti-inﬂammatory ICS therapy in
COPD and in asthma where up to 46% of older patients with
moderate disease do not respond at all to beclomethasone
[55]. The long-term consequences in nonresponding asth-
matics chronically treated with ICS are largely unknown but
maypredisposethiscohorttomorefrequentacuteexacerbat-
ionsandlungfunctiondeclineovertime.Thisiscomplicated
in the elderly adult who may have overlap features and does
not respond to therapy.
Asthma-COPD overlap may have origins in childhood,
for example, infections, atopy, and tobacco-smoking expo-
sure (Figure 6) but escapes earlier diagnosis because of cur-
rent deﬁnitions and guideline-based approaches to chronic
obstructive lung diseases. This could result in a heuristic bias
potentially overlooking patients in their 40s and 50s with
overlap syndrome by labeling them as lone “COPD” or par-
tially reversible “asthma.” This becomes even more relevant
in the elderly population (age ≥ 65 years) where the overlap
syndrome is increasingly recognized because of variable
responsetoguidelinedrugtherapy,morefrequenthealthcare
resource utilization [32–35, 56], and multiple comorbid
conditions [32].
3. Asthma-COPD OverlapSyndrome
The asthma-COPD overlap syndrome is not clearly deﬁned.
It is a syndrome in which older adults [7] with a signiﬁcant
smoking history have asthmatic features to their chronic ob-
structive airway disease. Individuals may have a history of
childhoodasthmaorasthmaasyoungadults.Therearemany
cases of pathologic and functional overlap between asthma
and COPD [11], yet authorities debate whether this overlap
syndrome represents the coexistence of two common airway
diseases or whether there are common underlying patho-
genic mechanisms leading to this common phenotype [15].
Overlap syndrome appears to share many of the same disease
risk factors as that of asthma and COPD (Figure 6). This
is a major challenge to our understanding of pathogenesis;
however, this observation can guide future basic studies and
the development of novel therapies.
The exact deﬁnition of this syndrome is evolving. For ex-
ample, Gibson and Simpson deﬁned overlap syndrome as
asthma and COPD, that is, “symptoms of increased variabil-
ity of airﬂow and incompletely reversible airﬂow obstruc-
tion,” [34] but this is rather limited when based solely on
FEV1 and bronchodilator response. For example, patients
with COPD can demonstrate a variable and signiﬁcant de-
gree of reversibility of airﬂow obstruction following bron-
chodilator challenge. Nearly 66% of COPD patients in the
UPLIFT trial improved their FEV1 by more than 15% after
receiving 80μg ipratropium and 400μg of salbutamol, yet
they were not considered to have overlap syndrome or con-
comitant asthma [57]. Thus, a clear deﬁnition remains elu-
sive regarding overlap syndrome since there is no consensus4 Journal of Allergy
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Figure 1: The prevalence of obstructive airway diseases in a small
cohort of general pulmonary clinic patients at the UC Davis Med-
ical Center. The category of “Other” represents a combination of
bronchitis,bronchiectasis,bronchiolitis,and/orcysticﬁbrosiscases.
The numbers within each bar above represent the percentage for
that group (∗P = 0.0003 and ∗∗P = 0.014 by Fisher’s exact test).
Fordeﬁnitionsofthediﬀerentdiagnosticgroups,pleaseseethetext.
in the literature. Moreover, the presence of exercise intol-
erance and static or dynamic hyperinﬂation and indices of
pulmonary emphysema in the aging patient may be im-
portant factors to include when considering overlap syn-
drome—a complex question needing further research.
Few studies have speciﬁcally investigated the asthma-
COPD overlap syndrome [3, 7]. Epidemiologic studies re-
p o r ta ne s t i m a t e dp r e v a l e n c eo f2 0 %[ 7, 8]. Patients with
coexisting asthma and COPD present similarly to pure asth-
maorCOPD,manifestingsignsandsymptomsofobstructive
lung physiology. However, patients with overlap syndrome
have worse lung function, more respiratory symptoms, and
a lower health-related quality of life than either disease alone
[58, 59]. They also consume more medical resources com-
pared to asthma or COPD alone, as much as 2 to 6 times
higher [3]. From a cost perspective alone (besides the impor-
tance of proper diagnosis and treatment), there is ample
reason to increase our research eﬀorts in this area.
Genetic linkage studies and genome-wide association
(GWA) studies have been of limited value in characterizing a
link between asthma and COPD. According to Postma et al.,
the paucity of GWA studies, assessing overlap syndrome and
the focus on clearly deﬁned outcomes which do not include
overlap, hampers the current insight genetic studies provide
[60]. In keeping with the Dutch Hypothesis, perhaps study-
ing the genes related to airway development (e.g., Wnt path-
way) and how these genes are altered in subjects with asthma
[61]andCOPD[62]mayprovidecluestolinkage.Onenota-
ble feature in many genetic and clinical studies is that precise
deﬁnitions of asthma-COPD overlap simply do not exist. In
order to understand the exact nature (genetic or otherwise)
of the asthma-COPD overlap syndrome, we must be able to
better deﬁne the entity.
Cigarette smoking interacts with the inﬂammation and
remodeling that occur in asthma and COPD [11]. The dis-
eases are most diﬀerent when nonsmoking asthmatics with
AHR and smokers with COPD but no AHR are compared.
Smoking inﬂuences the pattern of inﬂammation and steroid
responsiveness [63, 64]. Asthmatics who smoke have more
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Figure 2: The prevalence of obstructive airway diseases in a small
cohortofpatientsfromourtheUCDavisAsthmaNetwork(UCAN)
severe asthma clinic at the UC Davis Medical Center. The category
of “Other” represents a combination of bronchitis, bronchiectasis,
and/or bronchiolitis. The numbers within each bar above represent
the percentage for that group (∗P = 0.0009,
∗∗P < 0.0001, and
∗∗∗P < 0.0001byFisher’sexacttest).Fordeﬁnitionsofthediﬀerent
diagnostic groups, please see the text.
neutrophils in their airways, rather than eosinophils, resem-
bling COPD [63]. Smoking promotes neutrophilic inﬂam-
mation in both asthma and COPD which results in increased
steroid resistance [65, 66]. Disease severity increases as the
patterns of inﬂammation become more similar and steroid
resistance increases. Similarly, mucosal eosinophils increase
in acute exacerbations of mild COPD, a feature normally
seen in asthma [11]. This similarity in inﬂammatory re-
sponses may be one pathophysiologic link to the clinical phe-
notype of asthma-COPD overlap. Despite published defi-
nitions of asthma and COPD by international respiratory
societies such as ATS/ERS [4] and global initiatives such as
GINA [67]a n dG O L D[ 2], there remains considerable clin-
ical and pathologic overlap between these two disorders
which deﬁes such limited deﬁnitions [35].
Overlapsyndromeismoreprevalentintheagingpopula-
tion. In general, lung function tends to deteriorate naturally
withincreasedage.Elderlypatientswithasthmadisplaymore
features of ﬁxed obstruction than their younger counter-
parts, and they tend to have more severe symptoms [42, 68].
Their asthma may manifest as chronic persistent airﬂow ob-
struction mimicking COPD [69]. AHR also increases with
age where it is three times higher in the elderly compared to
nonelderlyadults[42].Ageisaveryimportantvariablewhen
assessing obstructive lung diseases given the known changes
in lung function that occur with increased age [70] and the
possibleroleofaginggenesespeciallyinCOPD[71].Because
of this age eﬀect, appropriate comparisons between asthma
and COPD should be made in patient cohorts with the same
or similar age, inhaled exposures, and disease severity. In-
deed, increasing age may be a powerful factor “blurring the
line” that separates asthma from COPD, thus, contributing
to the manifestation of overlap syndrome.
4. A DiagnosticDilemma: Our Experience
In our academic pulmonary clinics at the University of Cali-
fornia, Davis Medical Center (UCDMC), we have observed aJournal of Allergy 5
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Figure 3:Theprevalenceofobstructiveairwaydiseasesinourcom-
bined cohort of general pulmonary and UCAN severe asthma clinic
patients (N = 146) at the UC Davis Medical Center. The category
of “Other” represents a combination of bronchitis, bronchiectasis,
bronchiolitis, and/or cystic ﬁbrosis cases. The numbers within each
bar above represent the percentage for that group (∗P < 0.0001 and
∗∗P = 0.0005 by Fisher’s exact test). For deﬁnitions of the diﬀerent
diagnostic groups, please see the text.
signiﬁcant proportion of patients who present with an over-
lap of asthma and COPD. We deﬁned the overlap syndrome as
one of two clinical phenotypes: (1) allergic disease consistent
withasthma,thatis,variableairﬂowobstructionorAHRthat
is incompletely reversible (with or without emphysema or
reduced carbon monoxide diﬀusion capacity (DLCO)) or (2)
COPD with emphysema accompanied by reversible or par-
tially reversible airﬂow obstruction (with or without an al-
lergic syndrome or reduced DLCO). Patients must have dem-
onstrated either one of these to be diagnosed with “overlap
syndrome.”Reversibleairﬂowobstructionistraditionallyde-
ﬁned as an increase in FEV1 or FVC by ≥200mL and 12%
postbronchodilator challenge, and AHR is deﬁned by a posi-
tive methacholine challenge test. For those with clinical ﬁnd-
ings consistent with an asthma or COPD diagnosis, we fol-
lowed internationally agreed-upon deﬁnitions. Asthma was
deﬁned by the GINA executive summary criteria [67], as a
clinical syndrome with “variable, airﬂow obstruction within
the lung that is often reversible either spontaneously or with
treatment.” And COPD was deﬁned by the joint ATS/ERS
task force [4], as “a preventable and treatable disease state
characterized by airﬂow limitation that is not fully revers-
ible.” We used the ATS/ERS recommended lower limit of
the normal range for FEV1/FVC ratio (based on the 5th
percentile corrected for age, gender, height, and ethnicity) to
detect abnormal expiratory airﬂow obstruction in order to
avoid overdiagnosis of COPD.
The following data do not reﬂectthe entire patient popu-
lation in our academic general pulmonary or asthma referral
clinics but a smaller yet representative subset selected for
analysis. In the general pulmonary clinic cohort (Figure 1),
the prevalence of overlap syndrome is half that of asthma
(15.8% versus 34.2%, P = 0.014) and slightly over one-third
thatofCOPD/emphysema(15.8%versus43.4%,P=0.0003),
representing a sizable number of patients. Similarly in our
severe asthma clinics (the UC Davis Asthma Network
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Figure 5: The age distribution of the N = 29 subjects diagnosed
with overlap syndrome in the combined general pulmonary and
UCAN severe asthma clinics at the UC Davis Medical Center. The
values above each bar represent the percentage of patients within
t h ed e ﬁ n e da g eg r o u p( ∗P = 0.0024 by Fisher’s exact test).
(UCAN) Clinics, Figure 2), the prevalence of overlap syn-
drome is approximately half that of asthma (24.3% versus
52.9%, P = 0.0009), again representing a signiﬁcant propor-
tion of patients with mixed disease or “overlap.” Although
asthma is the most prevalent type of airway disease (43.1%),
when these data are assessed in aggregate (Figure 3), the
number of subjects with overlap syndrome approaches that
of COPD/emphysema (19.9% versus 23.3%, P = NS). This
simple observation underscores the commonplace diagnosis
of overlap syndrome in subspecialist pulmonary clinics at
UCDMC.
Patients with asthma tend to be younger (mean age 51.3
years old), those with COPD or emphysema tend to be older
by two decades (mean age 72.4 years old), and those with6 Journal of Allergy
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ically unique clinical phenotype. The progression from early life insults to pediatric disease and ﬁnally chronic obstructive airway disease in
adulthoodinvolvescomplexgenetic,epigenetic,andenvironmentalinteractions.Becausetheunderlyingpathogenicmechanismsthatleadto
the overlap syndrome have not be elucidated, we have no known disease-speciﬁc therapies other than those extrapolated from clinical trials
done in asthma- or COPD-only subjects. In this lies an opportunity for further research focused on the overlap syndrome as the “third arm”
of the most common obstructive airway diseases. Given that asthma-COPD overlap syndrome prevalence increases with age, knowledge
about this syndrome will have great clinical and economic implications for our aging population. †For deﬁnitions of the diﬀerent diagnostic
groups, please see the text. Abbreviations: inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), long-acting muscarinic antagonist
(LAMA), leukotriene receptor antagonist (LTRA), 5-lipoxygenase (5-LO), body mass index (BMI), airway hyperreactivity (AHR), and lung
volume reduction surgery (LVRS).
overlap syndrome are in between (mean age 66.7 years old).
The overlap group, however, was not signiﬁcantly younger
than the COPD/emphysema group (66.7 versus 72.4 years
old, P = NS; Figure 4). This is consistent with published ob-
servations that patients with overlap features tend to be
older (i.e. ≥ age 60), at least as compared to patients with
asthma. As the population ages, the prevalence of overlap
syndrome increases in each decade; the highest prevalence
being in those >60 years of age in our cohort (Figure 5). Our
observation that overlap syndrome prevalence increases with
age mirrors the data reported in much larger cohorts of ob-
structive lung disease [7, 34]. These data underline the im-
portance of this diagnosis in the elderly or aging population
andtheneedtobetterdistinguishamongstthevariouscauses
of chronic airﬂow obstruction, including overlap syndrome.
5. Treatment Approachfor the Asthma-COPD
Overlap Syndrome
In general, the principles of workup and treatment are sim-
ilar for asthma, COPD, and the overlap syndrome. Because
this syndrome is seen more commonly in older populations,
there may be a higher probability of adverse reactions to the
various classes of inhaled agents or systemic corticosteroids
[72]. Cognitive deﬁciencies leading to lower medication
compliance may be an issue, and general underdiagnosis and
undertreatment [42, 73, 74]m a yo c c u r .M a r t i n e ze ta l .r e c -
ommend treatment with a ICS/LABA combination, with or
without a long-acting anticholinergic agent (i.e., LAMA)
[75]. Smoking cessation, oxygen supplementation, pulmo-
nary rehabilitation, and vaccines are all reasonable interven-
tions. At present, there are no randomized clinical trial data
to help guide therapeutic interventions in overlap syndrome
[7, 53].
Basedonourclinicalexperience,werecommendasymp-
tom-targeted approach. For dynamic obstruction and/or hy-
perinﬂation, bronchodilators may provide the greatest bene-
ﬁt.WhetherLAMAsaloneorincombinationwithLABAsare
appropriate in overlap syndrome remains to be elucidated.
For patients in whom bronchospasm is described and/or
demonstrated, bronchodilators and ICSs are reasonable op-
tions. Adjunctive treatments such as leukotriene receptor
antagonists, 5-lipoxygenase inhibitors, methylxanthines, orJournal of Allergy 7
omalizumab deserve further study and should be adminis-
tered by pulmonary or allergy subspecialists. As the preva-
lence of overlap syndrome increases with age, targeting non-
respiratory age-related changes which may inﬂuence respira-
tory disease is paramount. This includes targeting nasal ob-
struction symptoms (due to non-allergic or allergic rhinitis,
mucosal dryness, or vasomotor symptoms) with nasal irriga-
tion, nasal steroids, and/or nasal anticholinergics [76, 77].
Additionally,treatingco-morbiditiessuchhasheartfailureor
chronic aspiration is important, especially GERD [78]o r
VCD which can be subclinical. These recommendations are
basedonourclinicalexperienceswiththeoverlappopulation
at UCDMC, where optimal treatment strategies still require
customization and additional study.
6. Concluding Remarks
Enough evidence exists to suggest that the current defini-
tions of asthma and COPD fail to capture the diverse range
of disease phenotypes. COPD, for example, is likely a heter-
ogeneous group of diseases with diﬀerent genetic back-
grounds and anatomic sites of pathology [79], and asthma
is no exception [38]. Whether the asthma-COPD overlap
syndrome is a separate entity or a hybrid point within a
spectrum of related diseases remains to be determined. One
certainty is that the overlap syndrome is clinically relevant
with a 20% prevalence in populations with airway diseases
(similar to 15.8% in our general pulmonary clinics, see
Figure 1). One proposal for improved understanding is to as-
sess similar-age patients with overlap features and well-char-
acterized small airway involvement. This would allow for a
more homogenous group with similar sites of pathologic
airwayinvolvementthatcanbebiopsiedandcorrelatedfunc-
tionally and clinically. Improved clinical data from this sub-
population of obstructive airways disease may reveal previ-
ouslyunderappreciatedpathophysiologic signatures andcre-
ate an opportunity for new and targeted therapies (Figure 6).
Earlier screening of the overlap syndrome is important
in current or former smokers in their 5th decade of life who
have partially reversible airways obstruction and progressive
exercise intolerance and variable (or no response) to guide-
line recommended asthma treatments. This approach can
providemoretimetoconductpharmacologicandnon-phar-
macologic interventions before patients become elderly or
develop severe disease.
Future investigations should include genetic studies, as-
sessment of aging genes expression, inﬂammatory proﬁles,
exhaled nitric oxide and other biomarkers, and airway biop-
sies to assess immune cell proﬁles and airway remodeling.
These data should then be correlated to historical (including
environmental exposure and other risk factors), clinical,
demographic, and physiological parameters. This will help
determine whether overlap syndrome is a unique phenotype
of obstructive lung disease. Currently, the treatment of over-
lap syndrome is extrapolated from guidelines for asthma or
COPD. It is unknown whether these common inhaled drugs
(ICS, LABAs, LAMAs), oral corticosteroids, leukotriene re-
ceptor antagonists, and so forth are eﬀective or appropriate
totreatthissyndrome.Therefore,futurebasicsciencestudies
and multicenter clinical trials should investigate disease
mechanisms while developing novel therapies. By studying
only those with “pure” asthma or COPD (in our clinical
trials) while excluding those with overlapping features, we
ignoreaconsiderableproportionofpatientswithobstructive
lung disease. With the aging of our population and the high
prevalence and cost of overlap syndrome, clinical trials and
further research are needed to investigate this unique popu-
lation of lung disease.
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